Allarity Therapeutics Files 8-K with Material Agreement
Ticker: ALLR · Form: 8-K · Filed: Mar 1, 2024 · CIK: 1860657
Sentiment: neutral
Topics: material-agreement, filing
Related Tickers: ALLR
TL;DR
ALLR filed an 8-K on 2/27/24 for a material agreement. Details to follow.
AI Summary
On February 27, 2024, Allarity Therapeutics, Inc. entered into a Material Definitive Agreement. The company also filed financial statements and exhibits as part of this report. The filing details are associated with accession number 0001213900-24-018789.
Why It Matters
This filing indicates a significant event for Allarity Therapeutics, Inc., potentially impacting its operations, financial standing, or strategic direction.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or alter existing ones for a company, requiring further analysis.
Key Players & Entities
- Allarity Therapeutics, Inc. (company) — Registrant
- February 27, 2024 (date) — Earliest event reported
- 0001213900-24-018789 (other) — Accession Number
- 24 School Street, 2nd Floor Boston, MA 02108 (address) — Principal executive offices
FAQ
What type of Material Definitive Agreement did Allarity Therapeutics, Inc. enter into?
The filing indicates the entry into a Material Definitive Agreement but does not specify the exact nature of the agreement in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on February 27, 2024.
What is the accession number for this filing?
The accession number for this filing is 0001213900-24-018789.
Where are Allarity Therapeutics, Inc.'s principal executive offices located?
Allarity Therapeutics, Inc.'s principal executive offices are located at 24 School Street, 2nd Floor, Boston, MA 02108.
What is the SEC file number for Allarity Therapeutics, Inc.?
The SEC file number for Allarity Therapeutics, Inc. is 001-41160.
Filing Stats: 703 words · 3 min read · ~2 pages · Grade level 11.8 · Accepted 2024-03-01 09:21:14
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ALLR The Nasdaq Stock Mar
Filing Documents
- ea0200995-8k_allarity.htm (8-K) — 28KB
- ea0200995ex10-1_allarity.htm (EX-10.1) — 12KB
- ea0200995ex99-1_allarity.htm (EX-99.1) — 22KB
- ex99-1_001.jpg (GRAPHIC) — 95KB
- ex99-1_002.jpg (GRAPHIC) — 700KB
- ex99-1_003.jpg (GRAPHIC) — 70KB
- ex99-1_004.jpg (GRAPHIC) — 257KB
- ex99-1_005.jpg (GRAPHIC) — 258KB
- ex99-1_006.jpg (GRAPHIC) — 219KB
- ex99-1_007.jpg (GRAPHIC) — 260KB
- ex99-1_008.jpg (GRAPHIC) — 368KB
- ex99-1_009.jpg (GRAPHIC) — 225KB
- ex99-1_010.jpg (GRAPHIC) — 51KB
- ex99-1_011.jpg (GRAPHIC) — 221KB
- ex99-1_012.jpg (GRAPHIC) — 249KB
- ex99-1_013.jpg (GRAPHIC) — 123KB
- ex99-1_014.jpg (GRAPHIC) — 325KB
- ex99-1_015.jpg (GRAPHIC) — 182KB
- ex99-1_016.jpg (GRAPHIC) — 101KB
- 0001213900-24-018789.txt ( ) — 5346KB
- allr-20240227.xsd (EX-101.SCH) — 3KB
- allr-20240227_lab.xml (EX-101.LAB) — 33KB
- allr-20240227_pre.xml (EX-101.PRE) — 22KB
- ea0200995-8k_allarity_htm.xml (XML) — 4KB
01 Entry into
Item 1.01 Entry into a Material Definitive Agreement. Amendment to Senior Convertible Notes On February 27, 2024, Allarity Therapeutics, Inc., a Delaware corporation ("we," "our," or the "Company") and 3i, LP, a Delaware limited partnership, (the "Holder" and together with us, the "Parties") entered into an Amendment to Senior Convertible Notes (the "Amendment") to two senior convertible notes dated as of January 18, 2024 and February 13, 2024 (each a "Note" and collectively the "Notes"). The Parties amended Section 4(c)(vi) of the Notes to clarify that the Holder cannot convert, nor can we issue our shares of common stock, if such issuance would necessitate stockholder approval by our trading market or exceed 19.9% of the shares of common stock. Except as so amended, all of the terms relating to the Notes continue in full force and effect. The description of the Amendment is qualified in its entirety by the full text of the Amendment, a copy of which is filed herewith as Exhibit 10.1, and which is incorporated herein by reference.
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On March 1, 2024, we provided updated corporate presentation slides about the Company (the "Corporate Presentation") on the Company's website. The Corporate Presentation may be used in presentations to investors, analysts and others. A copy of the Corporate Presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information reported under Item 7.01 in this Current Report on Form 8-K, and Exhibit 99.1 attached hereto are being "furnished" and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information contained herein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit Number Exhibit Description 10.1 Amendment Senior Convertible Notes 99.1 Company presentation slides 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on our behalf by the undersigned hereunto duly authorized. Allarity Therapeutics, Inc. Date: March 1, 2024 By: /s/ Thomas Jensen Thomas Jensen Chief Executive Officer 2